Significance of glomerular deposition of apolipoprotein (a) in various glomerulopathies

American Journal of Nephrology

Volumn 17, Issue 6, 1997, Pages 499-504

  Suzuki, Satoru ^a   Takahashi, Hoyu ^b   Sato, Hirokazu ^d   Takashima, Noriko ^c   Arakawa, Masaaki ^c   Gejyo, Fumitake ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

^d AKITA RED CROSS HOSPITAL   (Japan)

Author keywords

Apolipoprotein (a); Coagulation; Fibrinolysis; Glomerular disease; Lipoprotein (a)

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIPLASMIN; ANTITHROMBIN III; APOLIPOPROTEIN A; APOLIPOPROTEIN B100; CHOLESTEROL; D DIMER; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030700426     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000169177     Document Type: Article

References (34)

1. Schmits PG, Kasiske BL, O’Donnell MP. Keane WF: Lipids and progressive renal injury. Semin Nephrol 1989:9:354-369.
2. Moorhead JF: Lipid and progressive kidney disease. Kidney Int 1991;39(suppl 31):S35-S40.
3. Lee HS, Lee JS, Koh HI, Ko KW: Intraglo-merular lipid deposition in routine biopsies. Clin Nephrol 1991:36:67-75.
4. Sato H, Suzuki S, Kobavashi H, Inomata A, Ogino S, Arakawa M: Immunohistological localization of apolipoprotcins in the glomeruli in renal disease, specifically apoB and apoE. Clin Nephrol 1991;36:127-133.
5. Scanu AM, Lawn RM, Berg K: Lipoprotein (a) and atherosclerosis. Ann Intern Med 1991:115: 209-218.
6. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM: Human apolipoprotein (a) is homologous to plasminogen. Nature 1987;330:132-137.
7. Harpel PC, Gordon BR, Parker TS: Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sei USA 1989;86:3847-3851.
8. Miles LA, Fless GM, Levin EG, Scanu AM, Plow FF: A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 1989:339:301-303.
9. Loscalzo J, Weinfeld M, Hess GM, Scanu AM: Lipoprotein (a), fibrin binding and plasminogen activation. Arteriosclerosis 1990:10:240-245.
10. Leerink C, Duif P, Gimpel J, Kortlandt W, Bouma BN, von Rijn H: Lysine-binding heterogeneity of Lp(a): Consequences for fibrin binding and inhibition of plasminogen activation. Thromb Haemost 1992;68:185-188.
11. Scanu AM, Miles LA, Fless GM, Pfaffinger D, Eisenbart J, Jackson E, Hoover-Plow JL, Brunck T, Plow EF: Rhesus monkey lipoprotein (a) binds to lysine sepharose and U937 monocytoid cells less efficiently than human lipoprotein (a). J Clin Invest 1993:91:283-291.
12. Hervio L, Chapman MJ, Thillet J, Loyau S, Angles-Cano E: Does apolipoprotein (a) heterogeneity influence lipoprotein (a) effects on fibrinolysis? Blood 1993;82:392-397.
13. Halvorsen S, Skjonsberg OH, Berg K, Ruyter R, Godal HC: Does Lp(a) lipoprotein inhibit the fibrinolytic system? Thromb Res 1992:68: 223-232.
14. Garcia-Frade LJ, Alvarez JJ, Rayo I, Torrado MC, Lasuncion MA, Garcia Avello A, Hernandez A, Marin E: Fibrinolytic parameters and lipoprotein (a) levels in plasma of patients with coronary artery disease. Thromb Res 1991:63: 407-418.
15. Glucck CJ, Glucck HI, Trent T, Speis J, McCray C, Stroop D: Relationship between lipoprotein (a), lipids, apolipoprotcins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism 1993;42:236-246.
16. Molitemo DJ, Lange RA, Meidell RS, Willard JE, Lcltert CC, Gerard RD, Boerwinkle E, Hobbs HH, David Hillis L: Relation of plasma lipoprotein (a) to infarct artery patency in survivors of myocardial infarction. Circulation 1993;88:935-940.
17. Beisiegel U, Kita T, Anderson RGW, Schneider WJ, Brown MS, Goldstein JL: Immunologic cross-reactivity of the low-densitv lipoprotein receptor from bovine adrenal cortex, human fibroblasts, canine liver and adrenal gland, and rat liver. J Biol Chem 1981:256: 4071-4078.
18. Joven J, Villabona C, Vilella E, Masana L, Alberti R, Valles M: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990:323:579-584.
19. Keane WF, Kasiske BL: Hyperlipidemia in the nephrotic snvdrome. N Engl J Med 1990:323: 603-604.
20. Thomas ME, Freestone A, Varghesc Z, Pcrsaud JW. Moorhead JF: Lipoprotein (a) in patients with proteinuria. Nephrol Dial Transplant 1992;7:597-601.
21. Karadi I, Romics L, Palos G, Doman J, Kaszas I, Hesz A, Kostner GM: Lp(a) lipoprotein concentration in scrum of patients with heavy pro leinuria of different origin. Clin Chem 1989; 35:2121-2133.
22. Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL: Overexpression of human low-density lipoprotein receptors leads to accelerated catabolism of I.p(a) lipoprotein in transgenic mice. J Clin Invest 1990:85:1542-1547.
23. Wasserman J, Santiago A, Rifici V, Hollhoffer H, Scharschmidt L, Epstein M, Schlondorff D: Interaction of low density lipoprotein (LDL) with rat mesangial cells in vitro. Kidney lnt 1989:35:1168-1174.
24. Rayner HC, Horsburgh T, Brown SL, Lavender FL, Winder AF, Walls J: Receptor-mediated endocytosis of low-densitv lipoprotein by cultured human glomerular cells. Nephron 1990:55:292-299.
25. Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM: Interaction of recombinant alolipoprotcin (a) and lipoprotein (a) with macrophages. J Clin Invest 1991;87:767-771.
26. Salcncn EM, Jauhiainen M, Zardi L, Vahcri A, Ehnholm C: Lipoprotein (a) binds to fibronec-tin and serine proteinase activity capable of cleaving it. EMBO J 1989:8:4035-4040.
27. Levin EG, Miles LA, Hess GM, Scanu AM, Bavnham P, Curtiss LK, Plow EF: Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Artcrioscler Thromb 1994; 14:438-442.
28. Kincaid-Smith P: Coagulation and renal disease. Kidney lnt 1972:2:183-190.
29. Sato H, Suzuki S, Ueno M, Shimada H, Karasawa R, Nishi S, Arakawa M: Localization of apolipoprotein (a) and B-100 in various renal diseases. Kidney lnt 1993:43:430-435.
30. Suzuki S, Sato H, Shimada H, Takashima N, Kishimoto H, Ueno M, Nishi S, Wada K, Takahashi H, Shibata A, Arakawa M: Significance of glomerular deposition of plasmin-alpha 2-plasmin inhibitor complexes in various glomerulopathies. Clin Nephrol 1993:40:270-276
31. Walker FJ: Regulation of activated protein C by protein S: The role of phospholipid in factor VA inactivation. J Biol Chem 1981:256: 11128-11131.
32. Griffin JH, Evatl B, Zimmerman TS, Kleiss AJ, Wideman C: Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981:68:1370-1373.
33. Comp PC, Nixon RR, Cooper MR, Esmon CT: Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984;74: 2082-2088.
34. Vaziri ND, Alikhani S, Patel B, Nguyen Q, Barton CH, Gonzales EV: Increased levels of protein C activity, protein C concentration, total and free protein S in nephrotic syndrome. Nephron 1988:49:20-23.